| |
CR
|
PR
|
SD
|
PD
|
p value
|
|---|
|
Total (n = 363)
|
1 (0.3)
|
265 (73.0)
|
72 (19.8)
|
25 (6.9)
| |
|
E19del (n = 175)
| | | | |
0.785
|
|
Afatinib (n = 53)
|
0
|
38 (71.7)
|
12 (22.6)
|
3 (5.7)
| |
|
Erlotinib (n = 69)
|
1 (1.4)
|
54 (78.3)
|
10 (14.5)
|
4 (5.8)
| |
|
Gefitinib (n = 53)
|
0
|
40 (75.5)
|
11 (20.8)
|
2 (3.8)
| |
|
L858R (n = 154)
| | | | |
0.471
|
|
Afatinib (n = 38)
|
0
|
30 (78.9)
|
6 (15.8)
|
2 (5.3)
| |
|
Erlotinib (n = 61)
|
0
|
42 (68.9)
|
15 (24.6)
|
4 (6.6)
| |
|
Gefitinib (n = 55)
|
0
|
45 (81.8)
|
9 (16.4)
|
1 (1.8)
| |
|
Uncommon (n = 34)
| | | | |
0.332
|
|
Afatinib (n = 11)
|
0
|
6 (54.5)
|
3 (27.3)
|
2 (18.2)
| |
|
Erlotinib (n = 9)
|
0
|
4 (44.4)
|
4 (44.4)
|
1 (11..1)
| |
|
Gefitinib (n = 14)
|
0
|
6 (42.9)
|
2 (14.3)
|
6 (42.9)
| |
- Data are shown as n (%) per each group
- CR complete response, PR partial response, SD stable disease, PD progressive disease, E19del exon 19 deletion, L858R L858R point mutation, Uncommon uncommon mutations
